Evidence map›Paper›PMID 41591826›Full record

ReviewJournal of the American Society of Nephrology : JASN2026

Direct Measurement of GFR: Who, When, and How?: A Practical Approach Emphasizing Iohexol Plasma Clearance.

Elke Schaeffner, Natalie Ebert, Christine A White

Abstract readReview
In one paragraph

Review in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elke SchaeffnerInstitute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-7925-4577
Natalie EbertInstitute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-4463-3315
Christine A WhiteDepartment of Medicine, Queen's University, Kingston, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knowledge of kidney function is a key component for diagnosing CKD and initiating treatment. The eGFR, which is most commonly used in clinical practice as an approximation of kidney function, is the most practical for everyday use. It has, however, disadvantages because the two most common biomarkers used in eGFR calculations, creatinine and cystatin C, are influenced by patient characteristics such as body composition, inflammation, and many others, leading to significantly inaccurate GFR estimation at times. In patients who are prone to distorted eGFR values, measured GFR (mGFR) should be considered to ensure accurate assessment of kidney function. mGFR is not as influenced by patient characteristics as it uses exogenous biomarkers instead of endogenous ones. It is, however, more complex to perform and has also its limitations. Several different mGFR measurement methods exist. The one that has become most widely accepted and is the only method for which there is an internationally standardized protocol is plasma iohexol clearance. Other mGFR markers include iothalamate, mostly applied as urinary clearance and radioactive markers. Newer techniques that measure GFR transdermally have been developed, although they have yet to be sufficiently externally validated.

Indexed as

Glomerular Filtration RateIohexolRenal Insufficiency, ChronicBiomarkersCreatinineCystatin CHumansKidney Function TestsBiomarkersCreatinineCystatin CIohexolclinical sciencecreatinineGFR

Identifiers

PMID41591826
PMCPMC13065171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.